Abstracts tagged "Cohort Study"

Abstract Number: 1346 • ACR Convergence 2025
Preliminary Result of Investigating the Response of Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) Associated SNPs: One Cohort Study
YU Chen¹, Chien-Sheng Wu², Jacob Shujui Hsu³ and Pei-Lung Chen⁴, ¹Division of Rheumatology, Allergy and Immunology, Far Eastern Memorial Hospital, New Taipei City, Taiwan, R.O.C. Graduate Institute of Medical Genomics and Proteomics, National Taiwan University, Taipei, Taiwan, R.O.C., New Taipei City, Taiwan (Republic of China), ²Division of Rheumatology, Allergy and Immunology, Far Eastern Memorial Hospital, New Taipei City, Taiwan, R.O.C., New Taipei city, Taiwan (Republic of China), ³Graduate Institute of Medical Genomics and Proteomics, National Taiwan University, Taipei, Taiwan, R.O.C., Taipei city, Taiwan (Republic of China), ⁴Graduate Institute of Medical Genomics and Proteomics, National Taiwan University, Taipei, Taiwan, R.O.C., Taipei, Taiwan (Republic of China)
Background/Purpose: Multiple Single-Nucleotide Polymorphisms (SNPs), including those in the methotrexate and azathioprine metabolic pathways, are associated with poor response to conventional disease-modifying anti-rheumatic drugs (cDMARDs)…
Abstract Number: 1099 • ACR Convergence 2025
Safety and Effectiveness of Hydroxychloroquine in the Treatment of Rheumatic Immune-Related Adverse Events
Grace Haeun Lee¹, Gregory Challener², Janeth Yinh³, Jeffrey Sparks⁴, Kerry L. Reynolds⁵, Donald P. Lawrence⁵, Meghan J. Mooradian⁵, Ryan J. Sullivan⁵, Hyon K. Choi⁶ and Minna Kohler⁷, ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Massachusetts General Hospital, Boston, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁷Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) has been recommended [1-3] as a steroid-sparing agent for immune checkpoint inhibitor-inflammatory arthritis (ICI-IA), preferred due to its low immunosuppressive effect. However,…
Abstract Number: 0553 • ACR Convergence 2025
Modified A-Tool: An online self-screening tool for axial spondyloarthritis for patients with chronic back pain
Zeyu Tang¹ and Abhijeet Danve², ¹Yale School of Medicine, New Haven, CT, ²Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT
Background/Purpose: Lack of timely rheumatology referral of chronic back pain (CBP) patients with suspected axial spondyloarthritis (axSpA) is a major contributor to delayed diagnosis. We…
Abstract Number: 0385 • ACR Convergence 2025
Musculoskeletal Ultrasound Enhances Patient Insight and Clinical Decisions: A Multi-Center Study
Simran Nimal¹, Meridith Balbach², Aslam Fawad¹, Midori Nishio³ and Erin Chew², ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Vanderbilt University, Nashville, TN, ³John Muir Specialty Medical Group, Lafayette, CA
Background/Purpose: Musculoskeletal ultrasound (MSKUS) is a valuable tool for early detection and management of inflammatory arthritis.(1) Although integrated into rheumatology guidelines, training programs, and classification…
Abstract Number: 0158 • ACR Convergence 2025
Association between newer COVID-19 vaccines and COVID-19 related hospitalizations among people with autoimmune rheumatic diseases in the U.S. National COVID Cohort Collaborative (N3C)
Lesley Jackson¹, jerrod anzalone², Rahima Begum³, Fazlur Rahman¹, Namrata Singh⁴, Londyn Robinson⁵, Kaleb Michaud², Kenneth Saag⁶, Jasvinder Singh⁷, Rena Patel¹ and Maria I. ("Maio") Danila⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Nebraska Medical Center, Omaha, NE, ³University of Alabama at Birmingham, Birmingham, ⁴University of Washington, Bellevue, WA, ⁵University of Washington, Seattle, WA, ⁶The University of Alabama at Birmingham, Birmingham, AL, ⁷Baylor College of Medicine, Houston, TX, ⁸University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: People with autoimmune rheumatic diseases (AIRD) are at higher risk for serious complications and poor outcomes from COVID-19 infection. Data is lacking on outcomes…
Abstract Number: 2657 • ACR Convergence 2025
Incidence of Rheumatic Diseases Among Patients Receiving GLP-1 Receptor Agonists: A Comparative Analysis with DPP-4 Inhibitors in a Propensity Score-Matched Cohort
Betul Ibis¹, Furkan Bahar¹, Yu-Che Lee², Ko-Yun Chang³, Yu Chang⁴ and Cho-Han Chiang⁵, ¹Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, ²University at Buffalo, Buffalo, NY, ³National Jewish Health, Denver, CO, ⁴National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China), ⁵Mount Auburn Hospital, Harvard Medical School, Cambridge
Background/Purpose: GLP-1 receptor agonists (GLP-1RAs) are increasingly utilized in diabetes mellitus management due to their glucose-lowering and cardiovascular benefits. However, the effect of GLP-1RAs on…
Abstract Number: 2389 • ACR Convergence 2025
A Comparison of Patients with Older Onset vs. Younger Onset SLE: A Retrospective Cohort Study
Chelsea Guan¹, Milad Heydari-Kamjani², Keri Ann Pfeil¹, Elleson Harper¹, Lindsay Frumker³, Meghan Gump¹ and Omer Pamuk², ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ³University hospitals Cleveland medical center, Highland Heights, OH
Background/Purpose: SLE is a systemic autoimmune disease that can present at different ages and with various multiorgan complications. In this study, we aimed to analyze…
Abstract Number: 2074 • ACR Convergence 2025
Increased Mortality in Hispanic Males with Lymphopenia: A Descriptive and Statistical Analysis of Anti-Melanoma Differentiation-Associated Protein 5 (MDA-5) Antibody Positive Patients
Sergio Maldonado Chaar¹ and Kelly Corbitt², ¹University of Miami/Jackson Health, Miami, FL, ²University of Miami Miller School of Medicine, El Portal, FL
Background/Purpose: Anti-melanoma differentiation-associated protein 5 (MDA-5) antibody positivity in dermatomyositis (DM) is often associated with development of interstitial lung disease (ILD), with factors such as…
Abstract Number: 1842 • ACR Convergence 2025
Social Vulnerability Index, Type 2 Lupus Symptoms, and Select Dysregulated Immune Features Identify Stage 2 (Pre-classification) SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort
Melissa Munroe¹, Zoe Reed², Joel Guthridge², Diane Kamen³, Timothy Niewold⁴, Kendra Young⁵, Angel Weng⁵, Emma Wu⁵, Gary Gilkeson⁶, Michael Weisman⁷, Mariko Ishimori⁷, Daniel Wallace⁸, John Harley⁹, David Karp¹⁰, Jill Norris¹¹ and Judith James², ¹Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Medical University of South Carolina, Johns Island, SC, ⁴Hospital for Special Surgery, New York, New York, ⁵Colorado School of Public Health, Aurora, CO, ⁶Medical University of South Carolina, Charleston, SC, ⁷Cedars-Sinai Medical Center, LOS ANGELES, CA, ⁸Cedars Sinai Medical Center, Studio City, CA, ⁹US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹⁰UT Southwestern Medical Center, Dallas, TX, ¹¹Colorado School of Public Health, Denver, CO
Background/Purpose: Socioeconomic environmental factors are associated with SLE disease activity and early mortality and may contribute to disease progression in at-risk populations. Blood relatives (BRs)…
Abstract Number: 1541 • ACR Convergence 2025
Tofacitinib versus Belimumab in maintenance therapy of Systemic Lupus Erythematosus: A Real-World Study of the CSTAR cohort
Qizhi Yuan¹, Qinli Qin², Leyao Ma¹ and Mengtao Li³, ¹Peking Union Medical College Hospital, Beijing, China (People's Republic), ²Dongguan Kanghua Hospital, Dongguan, Guangdong, China (People's Republic), ³Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with multi-organ involvements and recurrent relapses. The objectives of treatment include ensuring long-term patient survival, preventing…
Abstract Number: 1339 • ACR Convergence 2025
Inflammatory Rheumatic Diseases in IDH-mutated Myeloid Neoplasms: Clinical Spectrum and Response to IDH Inhibitors
Romain Stammler¹, Peter Chen², Orianne Debeaupuis², Lin Pierre Zhao¹, Mirabelle Ruyer Thompson¹, Eve Zakine¹, Julien Rossignol¹, Lauriane Goldwirt¹, Thibault Comont³, Mael Heiblig⁴, Lionel Ades¹, Marie Sebert¹, Jean-sébastien Allain⁵, Julien Campagne⁶, Marie Anne Couturier⁷, Marina Cumin⁸, Marie Caroline Dalmas⁹, Guillaume Denis¹⁰, Cecile Devloo¹¹, Adrien De Voeght¹², Louis Drevon¹, Pierre Duffau¹³, Sophie georgin-Lavialle¹⁴, Delphine Gobert¹, Noemie Abisror¹⁵, Olivier Kosmider¹⁶, Fréderic Rieux-Laucat², Estibaliz LAZARO¹⁷, Jean Guillaume Lopez¹⁸, Alexandre Maria¹⁹, Wladimir Mauhin²⁰, Julie Merindol²¹, Claire Merlot²², Tristan Mirault¹, Laurent Pascal²³, François Perrin²⁴, Emmanuel Raffoux¹, Ramy Rahme²⁵, Damien Roos-Weil¹, Benjamin Terrier²⁶, Benjamin Torreau²⁷, Olivier Fain¹, Pierre Fenaux¹, Pierre Hirsch¹, Vincent Jachiet¹, Jerome Hadjadj¹ and Arsène Mekinian²⁸, ¹Assistance Publique des Hôpitaux de Paris, Paris, France, ²Imagine Institute, Paris, France, ³Centre Hospitalier Universitaire Toulouse Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France, ⁴Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, ⁵Scorff-Lorient Hospital, Lorient, France, ⁶Hospital Robert Schuman, Metz, France, ⁷Centre Hospitalier Régional et Universitaire de Brest, Brest, France, ⁸Centre hospitalier de Libourne, Libourne, France, ⁹Strasbourg University Hospital Center, Strasbourg, France, ¹⁰Centre Hospitalier Rochefort, Rochefort, France, ¹¹Centre hospitalier de Dieppe, Dieppe, France, ¹²CHU of Liège, Liège, Belgium, ¹³Groupe Hospitalier Saint-André, Bordeaux, France, ¹⁴Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ¹⁵Internal Medicine, CHU Saint-Antoine,, Paris, France, ¹⁶AP-HP, Hopital Cochin, Institut Cochin, CNRS UMR⁸¹⁰⁴, INSERM U¹⁰¹⁶ Université Paris Cité Paris France., PARIS, France, ¹⁷Bordeaux University Hospital, Pessac, France, ¹⁸Dupuytren University Hospital, Limoges, France, ¹⁹Saint-Eloi Hospital, Montpellier, France, ²⁰Croix Saint Simon Hospital, Paris, France, ²¹University Hospital of Nice, Nice, France, ²²Centre hospitaliser d’Orléans, Orléans, France, ²³Hôpital Saint-Vincent de Paul, Lille, France, ²⁴Centre Hospitalier de Saint-Nazaire, Saint Nazaire, France, ²⁵Assistance Publique des Hôpitaux de Paris, Bobigny, France, ²⁶Cochin Hospital, Paris, France, ²⁷Internal Medicine and Immunology, CHU Tours, Tours, France, ²⁸Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France
Background/Purpose: Clonal hematopoiesis has emerged as a key contributor to systemic inflammation, bridging hematologic and immune-mediated inflammatory disorders (IMIDs). Isocitrate dehydrogenase 1 and 2 (IDH1/2)…
Abstract Number: 1093 • ACR Convergence 2025
Rituximab Associated Risk for Progressive Multifocal Leukoencephalopathy Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Blake Baay¹, Lorien Nassi² and Zachary Most³, ¹Scottish Rite for Children, Dallas, TX, ²UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ³UT Southwestern, Dallas, TX
Background/Purpose: Rituximab is one of the many immunosuppressive medications used to treat SLE that can increase a patient’s risk for developing progressive multifocal leukoencephalopathy (PML),…
Abstract Number: 0838 • ACR Convergence 2025
Complete Renal Response and Long-Term, Progression-Free Survival in Adult Patients With Lupus Nephritis: A Retrospective Cohort Study in the United States
Lisa Lindsay¹, Shu Wang², Huong Trinh¹, Yunru Huang¹, William Pendergraft¹ and Brad Rovin³, ¹Genentech, Inc., South San Francisco, CA, ²Genesis Research LLC, Hoboken, NJ, ³The Ohio State University, Columbus, OH
Background/Purpose: Complete renal response (CRR) and flare prevention, as early markers of long-term kidney survival, are important outcomes in lupus nephritis (LN) clinical trials.Methods: This…
Abstract Number: 0343 • ACR Convergence 2025
Impact of Janus Kinase Inhibitors on Bone Mineral Density and Microarchitecture in Rheumatoid and Psoriatic Arthritis: Insights from a Real-World Cohort
Edgar Wiebe¹, Dörte Huscher², Zhivana Boyadzhieva³, Andriko Palmowski⁴, Sandra Hermann¹, Burkhard Muche⁴, Arnd Kleyer⁵, David Simon⁶, Gerhard Krönke⁷, Paula Hoff⁸ and FRANK BUTTGEREIT⁹, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁷Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁸Endokrinologikum Berlin, Medizinisches Versorgungszentrum (MVZ) am Gendarmenmarkt, Berlin, Berlin, Germany, ⁹Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Janus kinase (JAK) inhibitors are an important treatment option for rheumatoid arthritis (RA) and psoriatic arthritis (PsA). By disrupting pro-inflammatory cytokine signaling (e.g., IL-6,…
Abstract Number: 0137 • ACR Convergence 2025
Landscape of Primary Antiphospholipid Syndrome: Clinical Spectrum, Serology, and Predictors of Damage in a Single Center Cohort of 233 Patients
RITESH KUMAR MISHRA¹, SUBIN PHILIP², JAIDEV MENON², RIZWANA NAUSHAD², AISHWARYA GOPAL³, CHRISTINA MARIASELVAM², Chengappa Kavadichanda², Molly mary Thabah³ and VIR SINGH NEGI², ¹JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, Bhubaneswar, India, ²JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, Puducherry, India, ³JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, India
Background/Purpose: Primary Antiphospholipid Syndrome (APS) a systemic autoimmune prothrombotic disorder with long-term consequences. While secondary APS is well studied, large real-world cohorts of primary APS…

« Previous Page
1
…
5
6
7
8
9
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].